

Goat Anti-Plasminogen Activator / PLAU Antibody
Peptide-affinity purified goat antibody
Catalog # AF1839a

Specification

Goat Anti-Plasminogen Activator / PLAU Antibody - Product Information

| | |
|-------------------|---|
| Application | WB |
| Primary Accession | P00749 |
| Other Accession | NP_001138503 , 5328 |
| Reactivity | Human |
| Host | Goat |
| Clonality | Polyclonal |
| Concentration | 0.5mg/ml |
| Isotype | IgG |
| Calculated MW | 48523 |

Goat Anti-Plasminogen Activator / PLAU Antibody - Additional Information

Gene ID 5328

Other Names

Urokinase-type plasminogen activator, U-plasminogen activator, uPA, 3.4.21.73, Urokinase-type plasminogen activator long chain A, Urokinase-type plasminogen activator short chain A, Urokinase-type plasminogen activator chain B, PLAU

Format

0.5 mg IgG/ml in Tris saline (20mM Tris pH7.3, 150mM NaCl), 0.02% sodium azide, with 0.5% bovine serum albumin

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

Goat Anti-Plasminogen Activator / PLAU Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Goat Anti-Plasminogen Activator / PLAU Antibody - Protein Information

Name PLAU ([HGNC:9052](#))

Function

Specifically cleaves the zymogen plasminogen to form the active enzyme plasmin.

Cellular Location

Secreted.

Tissue Location

Expressed in the prostate gland and prostate cancers.

Goat Anti-Plasminogen Activator / PLAU Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Goat Anti-Plasminogen Activator / PLAU Antibody - Images



AF1839a (0.3 µg/ml) staining of 293 lysate (35 µg protein in RIPA buffer). Primary incubation was 1 hour. Detected by chemiluminescence.

Goat Anti-Plasminogen Activator / PLAU Antibody - Background

This gene encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. A specific polymorphism in this gene may be associated with late-onset Alzheimer's disease and also with decreased affinity for fibrin-binding. This protein converts plasminogen to plasmin by specific cleavage of an Arg-Val bond in plasminogen. Plasmin in turn cleaves this protein at a Lys-Ile bond to form a two-chain derivative in which a single disulfide bond connects the amino-terminal A-chain to the catalytically active, carboxy-terminal B-chain. This two-chain derivative is also called HMW-uPA (high molecular weight uPA). HMW-uPA can be further processed into LMW-uPA (low molecular weight uPA) by cleavage of chain A into a short chain A (A1) and an amino-terminal fragment. LMW-uPA is proteolytically active but does not bind to the uPA receptor. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Goat Anti-Plasminogen Activator / PLAU Antibody - References

Tumour budding, uPA and PAI-1 are associated with aggressive behaviour in colon cancer. Mørkl B, et al. J Surg Oncol, 2010 Sep 1. PMID 20740581.

A genetic association study of maternal and fetal candidate genes that predispose to preterm prelabor rupture of membranes (PROM). Romero R, et al. Am J Obstet Gynecol, 2010 Jul 29. PMID 20673868.

Insulin-like growth factors II exon 9 and E-cadherin-Pml I but not myeloperoxidase promoter-463, urokinase-ApaL I nor xeroderma pigmentosum polymorphisms are associated with higher susceptibility to leiomyoma. Hsieh YY, et al. Anticancer Res, 2010 Jun. PMID 20651370.

Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility hot-spot. Johnatty SE, et al. PLoS Genet, 2010 Jul 8. PMID 20628624.

Variation at the NFATC2 Locus Increases the Risk of Thiazolinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Bailey SD, et al. Diabetes Care, 2010 Jul 13. PMID 20628086.

Goat Anti-Plasminogen Activator / PLAU Antibody - Citations

- [Confluence switch signaling regulates ECM composition and the plasmin proteolytic cascade in keratinocytes.](#)